NOS3 and chronic kidney disease: Phospho-eNOS levels were not significantly different in losartan or mirabegron-treated CKD groups compared to the sham-operated group and were significantly decreased compared to the CKD group (Fig. 5c, Supplementary Fig. S5, and S6).